Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

CPI-006 + Pembrolizumab

Aliases
CPI-006 + pembrolizumab

1 clinical trial

13 indications

Indication
Renal Cell Cancer
Indication
Colorectal Cancer
Indication
Triple-Negative Breast Cancer
Indication
Cervical Cancer
Indication
Ovarian Cancer
Indication
Pancreatic Cancer
Indication
Endometrial Cancer
Indication
Sarcoma
Indication
Squamous Cell Carcinoma of the Head and Neck
Indication
Bladder Cancer
Indication
Metastatic Castration Resistant Prostate Cancer
Indication
Non-Hodgkin Lymphoma
Indication
NSCLC
Clinical trial
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Status: Completed, Estimated PCD: 2022-12-28